References
  1. Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis . 2021 Jan;80(1):71-87.
  2. Zhao Z, Ye C, Dong L. The off-label uses profile of tofacitinib in systemic rheumatic diseases. Int Immunopharmacol . 2020 Jun;83:106480.
  3. Liu S, Tang M, Cao Y, Li C. Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: review and update. Ther Adv Musculoskelet Dis . 2020 May;12: 1759720X20912865.
  4. Cheng W, Li F, Tian J, et al. New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations. J Inflamm Res . 2022 Apr;15:2365-2380.
  5. Xeljanz (tofacitinib): highlights of prescribing information. New York: Pfizer, 2023 (package insert).
  6. Fernández-Sánchez M, Ribes-Artero H, Romá-Sánchez E, et al. Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report. Birth Defects Res . 2021 Oct;113(17):1275-1279.
  7. Clowse ME, Feldman SR, Isaacs JD, et al. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.Drug Saf . 2016 Aug;39(8):755-62.
  8. Gerosa M, Argolini LM, Artusi C, et al. The use of biologics and small molecules in pregnant patients with rheumatic diseases. Expert Rev Clin Pharmacol . 2018 Oct;11(10):987-998.
  9. Gayed M, Gordon C. Pregnancy and rheumatic diseases.Rheumatology (Oxford) . 2007 Nov;46(11):1634-40.
  10. Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis . 2016 May;75(5):795-810.